SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Greene who wrote (1678)1/25/1999 5:13:00 PM
From: Biomaven  Read Replies (1) of 10280
 
Michael,

As I posted previously, I believe the Knoll composition of matter patent is due to expire in 2002 - it took umpteen years before they figured out it worked as a weight-loss drug and to get it approved. Knoll has recently applied for an automatic 5 year extension based on the time it spent getting regulatory approval. However, this extension may not impact SEPR's use of an active metabolite of sibutramine.

Knoll also has a whole bunch of use patents (like for weight-loss) with much later expiration dates. I'm not sure what the impact of these on SEPR is - arguably nothing.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext